Finanzen von Enliven Therapeutics Inc (ELVN)ELVNEnliven Therapeutics Inc

Evaluating the bottom line, Enliven Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -15.31%, provide a clear picture of how effectively ELVN converts its operational activities into shareholder value.

In the context of the broader market, ELVN competes directly with industry leaders such as DNLI and DYN. With a market capitalization of $3.04B, it holds a leading position in the sector. When comparing efficiency, ELVN's gross margin of N/A stands against DNLI's 76.61% and DYN's N/A. Such benchmarking helps identify whether Enliven Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Enliven has faced consistent net income losses, with Q2 2026 showing a net loss of $32.5 million and an EPS of -0.49, indicating ongoing profitability challenges. However, the company has a strong current ratio of 64.07, suggesting excellent liquidity.